What prescription regimen (dose, route, frequency, duration) should be used for Lansoprazole in a patient on phenytoin with a gastric ulcer?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 14, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Lansoprazole Prescription for Gastric Ulcer in Patient on Phenytoin

For a patient on phenytoin with a gastric ulcer, prescribe lansoprazole 30 mg orally once daily, taken 30 minutes before breakfast, for 8 weeks to achieve ulcer healing. 1

Dosing Rationale

The FDA-approved regimen for gastric ulcer healing demonstrates that lansoprazole 30 mg once daily achieves 96.8% healing rates at 8 weeks, significantly superior to placebo (76.7%) 1. While 15 mg and 60 mg doses also show efficacy, the 30 mg dose represents the optimal balance of effectiveness and safety, with healing rates of 58.1% at 4 weeks and 96.8% at 8 weeks 1.

Specific Prescription Details

  • Dose: 30 mg
  • Route: Oral (capsule; contents can be sprinkled on soft foods if swallowing is difficult) 2
  • Frequency: Once daily
  • Timing: 30 minutes before breakfast 3
  • Duration: 8 weeks for initial healing 1

Critical Drug Interaction Consideration

Important caveat: While lansoprazole has a relatively favorable interaction profile compared to omeprazole, there is potential for interaction with phenytoin through CYP450 metabolism 4. However, dexlansoprazole has been specifically shown to have no impact on phenytoin pharmacokinetics 4. If available and cost-equivalent, dexlansoprazole 30-60 mg daily may be preferable in this phenytoin-treated patient to avoid any theoretical interaction risk.

Monitor phenytoin levels if clinical signs of toxicity or loss of seizure control emerge, though clinically significant interactions with lansoprazole appear uncommon 4.

Maintenance Therapy Considerations

After documented ulcer healing at 8 weeks:

  • If H. pylori positive: Eradicate H. pylori using bismuth quadruple therapy or rifabutin triple therapy (both include lansoprazole 45 mg twice daily for 14 days as part of the regimen) 3
  • If H. pylori negative and ulcer healed: Consider maintenance therapy with lansoprazole 15 mg daily if high risk for recurrence 1
  • If phenytoin must continue long-term: Maintenance lansoprazole 15 mg daily has demonstrated 84-90% remission rates over 12 months 1

Alternative Dosing Scenarios

For H. pylori eradication (if testing confirms infection), lansoprazole dose increases to 45 mg twice daily (equivalent to 40 mg omeprazole twice daily) as part of combination antibiotic therapy for 14 days 3.

Related Questions

In a 78-year-old patient with acid peptic disease, is it preferable to consume milk or curd at night?
Can pantoprazole be taken concurrently with my other medications?
What are the causes of duodenal ulcers?
Does lansoprazole provide better gastric mucosal coating than other proton‑pump inhibitors?
In a 45-year-old man with a duodenal ulcer that healed after an 8‑week course of proton pump inhibitor (PPI) therapy, who has stopped nonsteroidal anti‑inflammatory drugs (NSAIDs) and was Helicobacter pylori‑negative, what is the appropriate next step: continue the PPI indefinitely, repeat endoscopy, perform H. pylori stool testing, or no further testing or treatment?
What is the diagnosis and recommended treatment for a patient with severe laryngeal pain triggered by minimal temperature decrease, wind or cold, refractory to anticonvulsant therapy?
Which peptic ulcer disease medication is compatible with phenytoin therapy?
What is the recommended antibiotic prophylaxis guideline for a patient with choledocholithiasis and cholelithiasis without acute cholecystitis, who is afebrile and has no leukocytosis?
What is the recommended antibiotic prophylaxis and peri‑procedural management for a patient undergoing endoscopic retrograde cholangiopancreatography (ERCP) with possible therapeutic intervention?
What is the diagnosis and treatment for soft palate myoclonus triggered by a decrease in temperature?
What are the risks associated with botulinum toxin (Botox) injection for palatal myoclonus?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.